A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby‐Arnon(Broad Institute), Charles H. Yoon(Brigham and Women's Hospital), Christopher Rodman(Broad Institute), Ryan J. Sullivan(Dana-Farber Cancer Institute), Bastian Schilling(Goethe University Frankfurt), Genevieve M. Boland(Harvard University), Rohit Thummalapalli(Memorial Sloan Kettering Cancer Center), Shaolin Mei(Harvard University), Parin Shah(Harvard University), Keith T. Flaherty(Cancer Research Center), Abhay Kanodia(Dana-Farber Cancer Institute), Orr Ashenberg(Broad Institute), Bokang Rabasha(Dana-Farber Cancer Institute), Meenhard Herlyn(The Wistar Institute), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Russell W. Jenkins(Broad Institute), Patrick Hwu(Moffitt Cancer Center), Dirk Schadendorf(National Center for Tumor Diseases), Asaf Rotem(AstraZeneca (South Korea)), Shu Wang(Harvard University), Adrienne Luoma(Harvard University), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Patrick A. Ott(Dana-Farber Cancer Institute), Johannes C. Melms(Columbia University Irving Medical Center), Rachel Leeson(Dana-Farber Cancer Institute), Shruti Malu(Dana-Farber Cancer Institute), Dennie T. Frederick(Broad Institute), Chantale Bernatchez(BMC Software (United States)), Bruce E. Johnson(Harvard University), Jia‐Ren Lin(Harvard University), Levi A. Garraway(Broad Institute), Claire Margolais(Dana-Farber Cancer Institute), David A. Barbie(Dana-Farber Cancer Institute), Peter K. Sorger(Harvard University Press), Elizabeth I. Buchbinder(Massachusetts General Hospital), Orit Rozenblatt–Rosen(Broad Institute), Michael S. Cuoco(Broad Institute), Adam N.R. Cartwright(Harvard University), Gao Zhang(Central South University), Alex K. Shalek(Broad Institute), F. Stephen Hodi(Harvard University), Tabea Moll(Johns Hopkins University), Israel Cañadas(Fox Chase Cancer Center), Rizwan Haq(Ontario Institute for Cancer Research), David Liu(University of Louisville), Benchun Miao(Massachusetts General Hospital), Mei-Ju Su(Dana-Farber Cancer Institute), Monika S. Kowalczyk(Broad Institute), Marie-Andrée Forget(The University of Texas MD Anderson Cancer Center), Itay Tirosh(Weizmann Institute of Science)
Cited by 1,456
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k